2013-02-14 08:35:00 -

Events for the full year 2012
Laquinimod
  * Phase III data presented at the AAN (64th Annual Meeting of the American
    Academy of Neurology)
  * Application submitted for regulatory approval in the EU, milestone payment
    of USD 5 M from Teva
  * Teva initiates a Phase III study in multiple sclerosis (the CONCERTO study)
    in the US
  * Positive Crohn's Phase II data presented at the UEGW conference
  * Teva expands the clinical development program to encompass new indications


TASQ
  * EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in Phase
    III study
  * overall survival data from Phase II   study presented
  * biomarker data presented at the ESMO conference
  * Ipsen initiated two new Phase II trials; a "switch maintenance" in prostate
    cancer and
    a second study into additional cancer forms
  * Phase III study fully enrolled (1,245 patients); milestone payment of EUR
    10 M from Ipsen


ANYARA
  * Phase II/III study in renal cell cancer concluded
  *  Results presented during Q1, 2013:
     - study did not achieve primary clinical endpoint
     - doubling of progression free survival and OS in 25 % of patients
     - planning of the continued clinical development ongoing


57-57
  * clinical trial of systemic sclerosis/scleroderma concluded

ISI
  * focus on patent submissions H1 2013
  * project proceeds as planned

                                              Oct - Dec            Jan -
Dec

 (MSEK)                              2012      2011      2012      2011
----------------------------------------------------------------------------
  *      Net sales                   91.5      3.3      227.9      234.6

  *      Operating profit/loss        5.5     -94.7     -163.2    -100.9

  *      Net profit/loss              0.1     -93.2     -175.0     -94.5

  *      Profit/loss per share (SEK)
                                      0.00    -1.35     -2.54      -1.38


For further information, please contact:

Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95

Hans Kolam, CFO Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00, Fax +46 (0)46 19 11 00
This report is also available at www.activebiotech.com


Active Biotech AB Year-end report Jan-Dec 2012: 
 hugin.info/1002/R/1678129/547591.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Active Biotech via Thomson Reuters ONE
[HUG#1678129]